Catalyst overview
Research summary
This catalyst tracks a Phase 2a data readout for BIIB122 (DNL151) in Parkinson's disease. The expected timing is based on the latest available company guidance and may change.
BEACON trial for LRRK2-Associated Parkinson’s Disease. 12/5/24- First participant dosed. 02/26/26:- Phase 2a BEACON study in LRRK2-associated Parkinson's disease remains ongoing. 05/07/26:- Phase 2a BEACON study in LRRK2-associated Parkinson's reiterated as ongoing; no data timing given. 08/06/26:- BEACON Ph2a data for LRRK2-associated Parkinson's expected in H1 2027.
Verification
Confirm timing and program details against the company announcement or filing.